Nayak AS, Settipane GA, Pedinoff A, Charous BL, Meltzer EO, Busse WW, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol. 2002;89:271–8. https://doi.org/10.1016/S1081-1206(10)61954-0. If the infection has already spread, the herbal active ingredient loosens the mucus in the upper and lower airways. With GeloMyrtol forte ® you can breathe freely again noticeably. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116:1289–95. https://doi.org/10.1016/j.jaci.2005.08.044.

The data of clinical studies will be input into Revman software (V.5.3) for data synthesis. The data will be synthesized and analyzed according to the level of statistical heterogeneity. If the study is homogeneous enough in terms of design and comparison, we will use a random-effect model for meta-analysis. If there is a large heterogeneity in the included trials, meta-analysis will not be carried out. We will try to find out the root causes of heterogeneity from various aspects and provide a narrative and qualitative summary. 2.5.1 Subgroup analysis and investigation of heterogeneity Neubauer and März tested the efficacy and toxicity of Sinupret (BNO 101) in a randomized double-blind placebo-controlled trial [ 9]. The trial included 160 patients with a diagnosis of acute bacterial sinusitis ( n = 81 in the Sinupret group and n = 79 in the placebo group). Sinupret or placebo were given as two sugar-coated tablets three times a day for 2 weeks alongside an antibiotic and a decongestant. Overall, patients in the Sinupret group had significantly better primary outcomes – radiographic findings and patient assessment of the therapy at the end of treatment – than patients receiving placebo. Likewise, patients in the Sinupret group reported a significant improvement in secondary outcomes, including mucosal swelling, nasal obstruction and headache, compared with patients in the placebo group. No significant toxicities were reported in either study group. The main limitation of this trial was the inclusion of male participants only.

Melzer J, Saller R, Schapowal A, Brignoli R. Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis. Forsch Komplementmed. 2006;13:78–87. https://doi.org/10.1159/000091969. Nedažnai. Gali pasireikšti virškinimo trakto negalavimų, pvz., skrandžio skausmas, diskomfortas epigastriume, skonio pakitimas. Gelomyrtol, a phytomedicine, is extracted from the leaves of Myrtaceae. It has been shown to have secretolytic, mucolytic, secretomotoric, and anti-inflammatory properties. [12–15] The efficacy of Gelomyrtol in the treatment of acute or chronic sinusitis has been confirmed in randomized controlled trials (RCTs) and recommended in German and international treatment guidelines. [16,17] Therefore, Gelomyrtol has the potential to be an effective adjuvant therapy for acute or chronic sinusitis. However, there is little evidence of its curative efficacy for acute or chronic sinusitis. Therefore, the aim of this study is to provide a comprehensive systematic review on the safety and efficacy of Gelomyrtol for patients with acute or chronic sinusitis. 1.1 Review objectives Skystina tirštas gleives bei veikia sekreciją, stimuliuoja ir lengvina atsikosėjimą. Tyrimų su gyvūnais metu, nustatyta, kad gleivių išsiskyrimas sustiprėja peroraliai pavartojus klinikines preparato dozes. Tai yra būtina sąlyga preparato, kaip sekretolitiko, vartojimui. Be sekretolitinio poveikio, tolimesniuose tyrimuose su gyvūnais ir in vitro tyrimų metu vartojant dideles dozes nustatytas antimikrobinis poveikis. Be to, tinkamuose modeliuose stebėtas priešuždegiminis poveikis. Apirbendrinus, visos šios savybės svarbio Gelomyrtol ir Gelomyrtol forte poveikiui.

Anti-inflammatory effects could be detected in suitable in vitro models, professional information GeloMyrtol® forte, as of February 2013 Evidence was strongest for Sinupret, followed by Pelargonium sidoides extract. Their use in acute rhinosinusitis is supported by randomized placebo-controlled trials demonstrating both clinical efficacy and safety. Comparative data with conventional treatments such as topical glucocorticosteroids were found only for Sinupret and suggested comparable efficacy in a small study.Christoph F, Kaulfers PM, Stahl-Biskup E. In vitro evaluation of the antibacterial activity of beta-triketones admixed to Melaleuca oils. Planta Med. 2001;67:768–71. https://doi.org/10.1055/s-2001-18350.

This review aims to assess the level and quality of evidence for the management of acute rhinosinusitis with herbal products and review their position in the context of other treatments. To this end, we have selected four herbal products for which high-level evidence was available from at least one double-blind randomized clinical trial involving approximately 100 patients or more, either versus placebo or in comparison with another active treatment: Sinupret®, Pelargonium sidoides extract, Cyclamen europaeum (CE), cineole, and GeloMyrtol forte®. To provide context for these data, we compared the strength of evidence of herbal products with that of the two synthetic treatments currently indicated for the management of acute rhinosinusitis, N-acetylcysteine and mometasone furoate. A further objective was to identify current knowledge gaps and future research directions for herbal products in managing acute rhinosinusitis. We will use a funnel plot to assess the reporting bias if ten or more studies are included. [23] 2.5 Data synthesis Rafinuotas rapsų aliejus, želatina, glicerolis (85 %), skystasis sorbitolis (nesikristalizuojantis) (E420), hipromeliozės acetatas-sukcinatas, trietilo citratas, natrio laurilsulfatas, talkas, dekstrinas, amonio glicirizatas, praskiesta vandenilio chlorido rūgštis.

Bachert C, Thakur M, Weyers S, Bittner C, Abramov-Sommariva D. Reporting clinical trial results of phytomedicines in acute rhinosinusitis: letter to the editor regarding Gottschlich S, Roschmann K, Candler H. Adv Ther (2018); 35:1023-1034. doi: 10.1007/s12325-018-0736-7. Adv Ther. 2019;36:1011–3. https://doi.org/10.1007/s12325-019-00933-6.

Children from 4 to 10 years of age take half of the adult dose - 1 capsule x 4-5 times daily in acute illnesses and 1 capsule x 3 times daily for chronic diseases.Sudedamosios medžiagos: Išgrynintų eukaliptų,saldžiųjų apelsinų,mirtų,citrinų eterinių aliejų mišinio(66:32:1:1)distiliatas Studies with N-acetylcysteine are limited to small-scale clinical trials, while MFNS is supported by a strength of evidence comparable to Sinupret in this indication. Conclusion